Felicia Tang1, Ehsan Malek1,2, Susan Math3, Christine L Schmotzer1,3, Rose C Beck1,3. 1. School of Medicine, Case Western Reserve University, Cleveland, OH. 2. Department of Hematology/Oncology, University Hospitals of Cleveland Medical Center, Cleveland, OH. 3. Department of Pathology, University Hospitals of Cleveland Medical Center, Cleveland, OH.
Abstract
OBJECTIVES: We investigated the frequency and pattern of detection of therapeutic monoclonal antibodies (t-mAbs) daratumumab and elotuzumab by routine serum protein electrophoresis (SPE) and immunofixation (IF) in treated patients with myeloma. METHODS: Detection of t-mAb was assessed in 22 patients by retrospective review of SPE/IF ordered prior to, during, and after 26 individual courses of therapy. RESULTS: t-mAb was distinguishable from M-protein in 16 of 26 courses, with daratumumab detected in nine of nine and elotuzumab in six of seven patients. t-mAb was detected on first follow-up SPE/IF in 12 patients, with earliest detection 7 days after therapy initiation and latest detection 70 days after therapy. t-mAb persisted throughout induction therapy in most patients, with loss of detection during maintenance daratumumab. CONCLUSIONS: When distinguishable from M-protein, t-mAbs are detectable in 93% of treated patients as soon as 7 days after the initial dose and are consistently observed throughout induction therapy, warranting increased monitoring and careful interpretation of SPE/IF.
OBJECTIVES: We investigated the frequency and pattern of detection of therapeutic monoclonal antibodies (t-mAbs) daratumumab and elotuzumab by routine serum protein electrophoresis (SPE) and immunofixation (IF) in treated patients with myeloma. METHODS: Detection of t-mAb was assessed in 22 patients by retrospective review of SPE/IF ordered prior to, during, and after 26 individual courses of therapy. RESULTS: t-mAb was distinguishable from M-protein in 16 of 26 courses, with daratumumab detected in nine of nine and elotuzumab in six of seven patients. t-mAb was detected on first follow-up SPE/IF in 12 patients, with earliest detection 7 days after therapy initiation and latest detection 70 days after therapy. t-mAb persisted throughout induction therapy in most patients, with loss of detection during maintenance daratumumab. CONCLUSIONS: When distinguishable from M-protein, t-mAbs are detectable in 93% of treated patients as soon as 7 days after the initial dose and are consistently observed throughout induction therapy, warranting increased monitoring and careful interpretation of SPE/IF.
Authors: Cyrille Hulin; Meral Beksac; Hugh J Goodman; Ivan Spicka; Adrian Alegre; Miles Prince; Frank Campana; Greg Finn; Solenn Le-Guennec; Sandrine Macé; Stéphane Muccio; Alexandra Tavernier; Marie-Claude Rouchon; Paul G Richardson Journal: Blood Cancer J Date: 2021-10-20 Impact factor: 11.037
Authors: Ashley Rose Scholl; Dimitrios Korentzelos; Taylor E Forns; Ethan K Brenneman; Matthew Kelm; Michael Datto; Sarah E Wheeler; Eric D Carlsen Journal: J Appl Lab Med Date: 2022-08-22
Authors: Elisabeth K M Mack; Sören Hartmann; Petra Ross; Ellen Wollmer; Christoph Mann; Andreas Neubauer; Cornelia Brendel; Jörg Hoffmann Journal: Ann Hematol Date: 2022-02-01 Impact factor: 3.673